Drug interactions between Norpace and Prograf
| Results for the following 2 drugs: |
|---|
| Norpace (disopyramide) |
| Prograf (tacrolimus) |
Interactions between your selected drugs
disopyramide ↔ tacrolimus
Applies to:Norpace (disopyramide) and Prograf (tacrolimus)
GENERALLY AVOID: Tacrolimus can cause dose-related prolongation of the QT interval. Theoretically, coadministration with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction. Pharmacokinetically, some of these agents (e.g., amiodarone, bepridil, disopyramide, dofetilide, quinidine) are also known to be substrates and/or inhibitors of CYP450 3A4 and may inhibit the metabolism of tacrolimus, which could lead to increased blood concentrations and toxicity.
MANAGEMENT: Tacrolimus should probably not be administered with class IA or class III antiarrhythmic agents unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. In addition, tacrolimus blood levels and renal function should be checked frequently when given with known substrates and/or inhibitors of CYP450 3A4, and the dosage adjusted accordingly.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
